4/16
01:32 pm
tvtx
How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]
Low
Report
How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]
4/15
10:36 pm
tvtx
A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]
Medium
Report
A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]
4/15
08:12 pm
tvtx
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
4/14
05:00 pm
tvtx
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/14
12:00 pm
tvtx
Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.
Medium
Report
Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.
4/14
11:10 am
tvtx
Travere Therapeutics (TVTX) had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a "buy" rating on the stock.
Low
Report
Travere Therapeutics (TVTX) had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a "buy" rating on the stock.
4/14
09:47 am
tvtx
Travere Therapeutics (TVTX) had its price target raised by Wedbush from $39.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
Travere Therapeutics (TVTX) had its price target raised by Wedbush from $39.00 to $44.00. They now have an "outperform" rating on the stock.
4/14
08:57 am
tvtx
Travere Therapeutics (TVTX) had its price target raised by Guggenheim from $49.00 to $54.00. They now have a "buy" rating on the stock.
Low
Report
Travere Therapeutics (TVTX) had its price target raised by Guggenheim from $49.00 to $54.00. They now have a "buy" rating on the stock.
4/14
08:00 am
tvtx
Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $47.00 price target on the stock.
Low
Report
Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $47.00 price target on the stock.
4/14
07:13 am
tvtx
Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by Citigroup Inc..
Medium
Report
Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by Citigroup Inc..
4/13
07:17 pm
tvtx
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS [Yahoo! Finance]
Medium
Report
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS [Yahoo! Finance]
4/13
06:16 pm
tvtx
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
High
Report
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
4/2
12:58 am
tvtx
Travere Awaits FDA FILSPARI Ruling As Valuation Gap Draws Attention [Yahoo! Finance]
Medium
Report
Travere Awaits FDA FILSPARI Ruling As Valuation Gap Draws Attention [Yahoo! Finance]
3/25
10:56 am
tvtx
Travere Therapeutics (TVTX) had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an "overweight" rating on the stock.
Low
Report
Travere Therapeutics (TVTX) had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an "overweight" rating on the stock.
3/17
01:52 pm
tvtx
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli [Yahoo! Finance]
Low
Report
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli [Yahoo! Finance]
3/10
08:14 am
tvtx
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) [Yahoo! Finance]
Low
Report
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) [Yahoo! Finance]
2/24
10:23 am
tvtx
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory [Yahoo! Finance]
2/24
07:42 am
tvtx
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]
Low
Report
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]
2/24
07:10 am
tvtx
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 [Yahoo! Finance]
2/23
12:32 pm
tvtx
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress [Yahoo! Finance]
Medium
Report
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress [Yahoo! Finance]
2/20
12:16 am
tvtx
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/19
07:23 pm
tvtx
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates [Yahoo! Finance]
Medium
Report
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates [Yahoo! Finance]
2/19
05:06 pm
tvtx
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss [Yahoo! Finance]
Medium
Report
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss [Yahoo! Finance]
2/19
04:01 pm
tvtx
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2/18
01:24 am
tvtx
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market [Yahoo! Finance]
Low
Report
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market [Yahoo! Finance]